Home
Diseases
Atherosclerotic Cardiovascular Disease

Atherosclerotic Cardiovascular Disease

Disease

Disease Profile

Atherosclerotic cardiovascular disease (ASCVD) is cardiovascular disease caused by atherosclerotic plaque buildup in arterial walls, leading to conditions such as coronary artery disease, stroke, and peripheral arterial disease.

Category: Cardiovascular disease

ICD Codes

I25.1

Related News

Arrowhead Pharmaceuticals Reports Strong Long-Term Data for Plozasiran in Hypertriglyceridemia

Mar 29, 2026

Arrowhead Pharmaceuticals presented long-term data showing plozasiran achieved 83% median triglyceride reduction in severe hypertriglyceridemia patients with no acute pancreatitis events over two years. The RNA interference therapy demonstrated durable improvements in atherogenic lipoproteins and consistent safety profile. The company plans to complete Phase 3 studies by mid-2026 and submit for regulatory approval.

Eli Lilly Acquires Rights to CSL's IL-6 Inhibitor in $100M Deal

Mar 26, 2026

Eli Lilly has acquired rights to CSL's IL-6 inhibitor clazakizumab in a $100 million deal, expanding its cardiometabolic pipeline. The monoclonal antibody targets chronic inflammation, particularly in cardiovascular conditions. This move follows Lilly's successful obesity and diabetes drugs that drove $65.1 billion in 2025 revenue.

Shingles Vaccine Reduces Cardiovascular Events in Heart Disease Patients by 46%

Mar 26, 2026

A new study of over 246,000 heart disease patients shows the shingles vaccine reduces major cardiovascular events by 46% and death by 61% within one year. The protective effects are comparable to quitting smoking and support existing vaccine recommendations for adults over 50. The findings will be presented at the American College of Cardiology's annual meeting.

Oral Semaglutide Shows Broad Cardiometabolic Benefits in Type 2 Diabetes Trial

Mar 25, 2026

Oral semaglutide demonstrated significant improvements in multiple cardiometabolic risk factors in adults with type 2 diabetes at high cardiovascular risk. The SOUL trial analysis showed reductions in systolic blood pressure, cholesterol, triglycerides, HbA1c, and body weight compared to placebo. These benefits were observed as early as 13 weeks and contributed to a 14% reduction in major adverse cardiovascular events.

Merck to Present Cardio-Pulmonary Pipeline Data at ACC.26, Including Phase 3 Enlicitide Results

Mar 17, 2026

Merck will present late-breaking clinical data from its cardio-pulmonary pipeline at ACC.26, including positive Phase 3 results for enlicitide, an investigational oral PCSK9 inhibitor, and Phase 2 data for WINREVAIR in heart failure patients.

Studies Support Combined SGLT2 Inhibitor and GLP-1 Therapy for Type 2 Diabetes Management

Mar 14, 2026

New clinical evidence demonstrates that combining SGLT2 inhibitors with GLP-1 receptor agonists provides additive benefits for type 2 diabetes patients, while machine learning tools help personalize therapy selection.

Oral PCSK9 Inhibitor Enlicitide Reduces LDL Cholesterol in Phase 3 Trial

Mar 05, 2026

Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.

Oral Semaglutide Reduces Heart Failure Events in Type 2 Diabetes Patients With Prior HF

Mar 03, 2026

A secondary analysis of the SOUL trial shows oral semaglutide significantly lowers heart failure-related events in type 2 diabetes patients with preexisting heart failure, particularly those with preserved ejection fraction, without increasing serious adverse events.

GLP-1 Receptor Agonists Show Greater Weight Loss in Women, Market to Reach $112.62 Billion by 2032

Mar 03, 2026

A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.

FDA Draft Guidance on Genome Editing Could Accelerate CRISPR Therapeutics Rare Disease Pipeline

Feb 26, 2026

The FDA has issued draft guidance that may speed approval pathways for rare disease therapies using genome editing technologies, potentially benefiting CRISPR Therapeutics' pipeline of six clinical-stage candidates.

Related Clinical Trials

NCT ID	Title	Status	Phase
NCT07594392	Clinical Assessment and Targeted Imaging to Characterize High-Risk Atherosclerotic Cardiovascular Disease of Survivors in SJLIFE	NOT_YET_RECRUITING
NCT07551492	A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease	NOT_YET_RECRUITING	PHASE3
NCT07543731	A Real-World Study of Long-Term Adherence and Persistence to Inclisiran, Evolocumab, and Alirocumab	NOT_YET_RECRUITING
NCT07203677	Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)	COMPLETED
NCT07160829	Focus on Levels of Awareness and Perceptions Regarding hsCRP in Identifying Systemic Inflammation in ASCVD, CKD and Heart Failure Management	COMPLETED
NCT07037433	Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity	RECRUITING	PHASE3
NCT07034690	Study to Evaluate the Impact of a Targeted Lipid Optimization Program on LDL-C Control in At-risk Adult Patients With Dyslipidemia	RECRUITING	PHASE4
NCT07023445	Patterns of Inclisiran Use in the Real World: An Analysis of US Databases	COMPLETED
NCT06962488	Polygenic Risk Score Implementation and Stratification for Managing Blood Pressure	RECRUITING	NA
NCT06875973	Pelacarsen Roll-over Extension Program	RECRUITING	PHASE3